A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)

British Journal of Cancer

Volumn 116, Issue 4, 2017, Pages 472-478

  Hall, P S ^a   Lord, S R ^b   Collinson, M ^c   Marshall, H ^c   Jones, M ^c   Lowe, C ^d   Howard, H ^c   Swinson, D ^c   Velikova, G ^c   Anthoney, A ^c   Roy, R ^e   Dent, J ^f   Cheeseman, S ^g   Last, K ^g,h   Seymour, M T ^d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d NIHR Clinical Research Network Coordinating Centre   (United Kingdom)

^e CASTLE HILL HOSPITAL   (United Kingdom)

^f HUDDERSFIELD ROYAL INFIRMARY   (United Kingdom)

^g YORK HOSPITAL   (United Kingdom)

^h BRADFORD ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIRUBICIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; PLATINUM COMPLEX;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; DIARRHEA; ESOPHAGUS CANCER; FEASIBILITY STUDY; FEMALE; FRAIL ELDERLY; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; ADENOCARCINOMA; CLINICAL TRIAL; DISEASE COURSE; ESOPHAGEAL NEOPLASMS; MORTALITY; PALLIATIVE THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROCEDURES; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; DEOXYCYTIDINE; DISEASE PROGRESSION; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; FRAIL ELDERLY; HUMANS; MALE; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE;

EID: 85009775887     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.442     Document Type: Article

References (19)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376
2. Alderson D, Langley RE, Nankivell MG, Blazeby JM, Griffin M, Crellin A, Grabsch HI, Okines AFC, Goldstein C, Falk S, Thompson J, Krysztopik R, Coxon FY, Pritchard S, Langer R, Stenning SP, Cunningham D (2015) Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072). J Clin Oncol 33: (suppl; abstr 4002)
3. Arain M, Campbell MJ, Cooper CL, Lancaster GA (2010) What is a pilot or feasibility study? A review of current practice and editorial policy. BMC Med Res Methodol 10: 67
4. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383
5. Cunningham D, Okines AF, Ashley S (2010) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 362: 858-859
6. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36-46
7. Guigoz Y, Vellas BJ (1997) Malnutrition in the elderly: the Mini Nutritional Assessment (MNA). Ther Umsch 54: 345-350
8. Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, Andre T, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Boucher E, Rebischung C, Hammel P, Rougier P, Bedenne L, Bouche O (2014) Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J Clin Oncol 32: 3520-3526
9. Kind P (1996) The EuroQoL instrument: an index of health-related quality of life. In Quality of Life and Pharmacoeconomics in Clinical Trials, Spiker B (ed), Lippincott-Raven: Philadelphia, pp 191-201
10. Lagergren P, Fayers P, Conroy T, Stein HJ, Sezer O, Hardwick R, Hammerlid E, Bottomley A, Van Cutsem E, Blazeby JM, European Organisation for Research Treatment of Cancer Gastrointestinal and Quality of Life Groups (2007) Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophagogastric junction and the stomach. Eur J Cancer 43: 2066-2073
11. Nouri FM, Lincoln NB (1987) An extended activities of daily living scale for stroke patients. Clin Rehabil 1: 301-305
12. Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D (1999) Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17: 2412-2418
13. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345: 1091-1097
14. Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O'Mahony MS, Maughan TS, Parmar M, Langley RE, FOCUS2 Investigators, National Cancer Research Institute Colorectal Cancer Clinical Studies Group (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 377: 1749-1759
15. Shitara K, Muro K, Matsuo K, Ura T, Takahari D, Yokota T, Sawaki A, Kawai H, Ito S, Munakata M, Sakata Y (2009) Chemotherapy for patients with advanced gastric cancer with performance status 2. Gastrointest Cancer Res 3: 220-224
16. Simonsick EM, Gardner AW, Poehlman ET (2000) Assessment of physical function and exercise tolerance in older adults: reproducibility and comparability of five measures. Aging (Milano) 12: 274-280
17. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ (1995) Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 75: 11-17
18. Trumper M, Ross PJ, Cunningham D, Norman AR, Hawkins R, Seymour M, Harper P, Iveson T, Nicolson M, Hickish T (2006) Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials. Eur J Cancer 42: 827-834
19. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y (2013) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 14: 481-489